SSJR has successfully moved the Court of Appeals for the Federal Circuit to require an additional $130 million bond from AstraZeneca, adding to existing bonds of $312 million, to allow recovery of damages and costs sustained by SSJR’s client Apotex as a result of an injunction. If the trial court’s recent decision finding AstraZeneca’s patent invalid is affirmed by the appellate court, Apotex will make a claim for damages and costs to recover these damages.